110 related articles for article (PubMed ID: 2250951)
1. [Comparative study of the tumor regression rate of 127 uveal melanomas irradiated with 106 Ru/106 Rh. Attempted analysis of the correlations between per-operative cytology and histopathology of the enucleated eye and the tumoral regression on the one hand, and general prognosis on the other hand].
Grange JD; Thacoor S; Bievelez B; Jean-Louis B; Baute B; Gérard JP; Sentenac I; Fontanière B; Bailly C
Ophtalmologie; 1990; 4(3):221-4. PubMed ID: 2250951
[TBL] [Abstract][Full Text] [Related]
2. [The role of beta-ray therapy in the treatment of choroidal and ciliary body melanomas].
Grange JD; Gérard JP; Ragab M; Delaroche G; Jean-Louis B; Bievelez B; Sentenac I; Baute B
Ophtalmologie; 1989; 3(3):175-9. PubMed ID: 2641104
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
[TBL] [Abstract][Full Text] [Related]
4. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
6. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.
Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T
Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534
[TBL] [Abstract][Full Text] [Related]
7. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
9. [Preoperative irradiation before enucleation in malignant melanoma of the uvea. Review of the literature and initial personal experiences].
Bornfeld N; Huser U; Sauerwein W; Wessing A; Sack H
Klin Monbl Augenheilkd; 1989 Apr; 194(4):252-60. PubMed ID: 2657203
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
12. A clinicopathological study of seven globes enucleated after primary radiation therapy for malignant melanoma of the choroid or ciliary body.
Liszauer AD; Brownstein S; Corriveau C; Deschênes J
Can J Ophthalmol; 1990 Dec; 25(7):340-4. PubMed ID: 2090338
[TBL] [Abstract][Full Text] [Related]
13. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.
Gragoudas ES; Lane AM; Munzenrider J; Egan KM; Li W
Trans Am Ophthalmol Soc; 2002; 100():43-8; discussion 48-9. PubMed ID: 12545676
[TBL] [Abstract][Full Text] [Related]
14. Cobalt plaque radiotherapy versus enucleation for posterior uveal melanoma: comparison of survival by prognostic index groups.
Augsburger JJ; Gamel JW; Shields JA
Trans Am Ophthalmol Soc; 1989; 87():348-59; discussion 359-61. PubMed ID: 2562523
[No Abstract] [Full Text] [Related]
15. Histopathologic findings in large uveal melanomas after brachytherapy with iodine 125 ophthalmic plaques.
Schilling H; Bornfeld N; Friedrichs W; Pauleikhoff D; Sauerwein W; Wessing A
Ger J Ophthalmol; 1994 Aug; 3(4-5):232-8. PubMed ID: 7804109
[TBL] [Abstract][Full Text] [Related]
16. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
17. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
18. Have choroidal and ciliary body melanomas changed during the period 1955-2000?
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):509-16. PubMed ID: 15453845
[TBL] [Abstract][Full Text] [Related]
19. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma.
Chaudhry IA; Liu M; Shamsi FA; Arat YO; Shetlar DJ; Boniuk M
Retina; 2009 Jan; 29(1):73-9. PubMed ID: 18728617
[TBL] [Abstract][Full Text] [Related]
20. Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas.
Toivonen P; Mäkitie T; Kujala E; Kivelä T
Curr Eye Res; 2003 Oct; 27(4):237-45. PubMed ID: 14562175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
